Statin use and survival in patients with metastatic castration-resistant prostate cancer treated with abiraterone or enzalutamide after docetaxel failure: the international retrospective observational STABEN study

BACKGROUND: Statins may potentiate the effects of anti-hormonal agents for metastatic castration-resistant prostate cancer (mCRPC) through further disruption of essential steroidogenic processes. We investigated the effects of statin use on clinical outcomes in patients with mCRPC receiving abirater...

Descripción completa

Detalles Bibliográficos
Autores principales: Gordon, Jacob A., Buonerba, Carlo, Pond, Gregory, Crona, Daniel, Gillessen, Silke, Lucarelli, Giuseppe, Rossetti, Sabrina, Dorff, Tanya, Artale, Salvatore, Locke, Jennifer A., Bosso, Davide, Milowsky, Matthew Ivan, Witek, Mira Sofie, Battaglia, Michele, Pignata, Sandro, Cherhroudi, Cyrus, Cox, Michael E., De Placido, Pietro, Ribera, Dario, Omlin, Aurelius, Buonocore, Gaetano, Chi, Kim, Kollmannsberger, Christian, Khalaf, Daniel, Facchini, Gaetano, Sonpavde, Guru, De Placido, Sabino, Eigl, Bernhard J., Di Lorenzo, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2018
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5929432/
https://www.ncbi.nlm.nih.gov/pubmed/29731989
http://dx.doi.org/10.18632/oncotarget.24888

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5929432/
https://www.ncbi.nlm.nih.gov/pubmed/29731989
http://dx.doi.org/10.18632/oncotarget.24888

Ejemplares similares